Purpose

To develop a framework for prospective free-induction decay (FID)-based navigator gating for suppression of motion artifacts in carotid magnetic resonance imaging (MRI) and to assess its capability in vivo.

Materials and methods

An FID-navigator, comprising a spatially selective low flip-angle sinc-pulse followed by an analog-to-digital converter (ADC) readout, was added to a conventional turbo spin-echo (TSE) sequence. Real-time navigator processing delivered accept/reject-and-reacquire decisions to the sequence. In this Institutional Review Board (IRB)-approved study, seven volunteers were scanned with a 2D T2-weighted TSE sequence. A reference scan with volunteers instructed to minimize motion as well as nongated and gated scans with volunteers instructed to perform different motion tasks were performed in each subject. Multiple image quality measures were employed to quantify the effect of gating.

Results

There was no significant difference in lumen-to-wall sharpness (2.3 ± 0.3 vs. 2.3 ± 0.4), contrast-to-noise ratio (CNR) (9.0 ± 2.0 vs. 8.5 ± 2.0), or image quality score (3.1 ± 0.9 vs. 2.6 ± 1.2) between the reference and gated images. For images acquired during motion, all image quality measures were higher (P < 0.05) in the gated compared to nongated images (sharpness: 2.3 ± 0.4 vs. 1.8 ± 0.5, CNR: 8.5 ± 2.0 vs. 7.2 ± 2.0, score: 2.6 ± 1.2 vs. 1.8 ± 1.0).

Conclusion

Artifacts caused by the employed motion tasks deteriorated image quality in the nongated scans. These artifacts were alleviated with the proposed FID-navigator.

Purpose

To determine whether readout-segmented echo-planar diffusion imaging (RESOLVE) improves separation of malignant versus benign lesions compared to standard single-shot echo-planar imaging (ss-EPI) on BI-RADS 4/5 lesions detected on breast magnetic resonance imaging (MRI).

Materials and methods

Consecutive 3T breast MRI studies with BI-RADS 4/5 designation and subsequent biopsy or benign mastectomy were retrospectively identified. Freehand regions of interest (ROIs) were drawn on lesions and also on normal background fibroglandular tissue for comparison. Lesion-to-background contrast was evaluated by normalizing signal intensity of the lesion ROI by the normal background tissue ROI at b = 800. Statistical analysis used the Mann-Whitney/Wilcoxon rank-sum test for unpaired and Wilcoxon signed-rank for paired comparisons.

Results

Of 38 lesions in 32 patients, 10 were malignant. Lesion-to-background contrast was higher on RESOLVE than ss-EPI (1.80 ± 0.71 vs. 1.62 ± 0.63, P = 0.03). Mean apparent diffusion coefficient (ADC) was the same or lower on RESOLVE than ss-EPI, and this effect was largest in malignant lesions (RESOLVE 0.90 ± 0.13; ss-EPI 1.00 ± 0.13; median difference -0.10 (95% confidence interval [CI]: -0.17, -0.02) × 10(-3) mm(2) /sec; P = 0.014). By either diffusion method, there was a statistically significant difference between benign and malignant mean ADC (P < 0.001).

Conclusion

Increased lesion-to-background contrast and improved separation of benign from malignant lesions by RESOLVE compared to standard diffusion suggests that RESOLVE may show promise as an adjunct to clinical breast MRI.